Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 6
2014 9
2015 9
2016 9
2017 9
2018 11
2019 5
2020 7
2021 10
2022 3
2023 3
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, Ito T, Kambarov Y, Llorca PM, Oliveira-Maia AJ, Messer T, Mulhern-Haughey S, Rive B, von Holt C, Young AH, Godinov Y; ESCAPE-TRD Investigators. Reif A, et al. Among authors: buyze j. N Engl J Med. 2023 Oct 5;389(14):1298-1309. doi: 10.1056/NEJMoa2304145. N Engl J Med. 2023. PMID: 37792613 Free article. Clinical Trial.
Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W, Egeberg A, Sonkoly E, Gorecki P, Tjärnlund A, Buyze J, Wegner S, McGonagle D. Tillett W, et al. Among authors: buyze j. Arthritis Res Ther. 2023 Sep 15;25(1):169. doi: 10.1186/s13075-023-03138-z. Arthritis Res Ther. 2023. PMID: 37715294 Free PMC article. Clinical Trial.
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
McIntyre RS, Bitter I, Buyze J, Fagiolini A, Godinov Y, Gorwood P, Ito T, Oliveira-Maia AJ, Vieta E, Werner-Kiechle T, Young AH, Reif A. McIntyre RS, et al. Among authors: buyze j. Eur Neuropsychopharmacol. 2024 Aug;85:58-65. doi: 10.1016/j.euroneuro.2024.05.009. Epub 2024 Jul 1. Eur Neuropsychopharmacol. 2024. PMID: 38954874 Free article. Clinical Trial.
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C. Puig L, et al. Among authors: buyze j. Am J Clin Dermatol. 2024 Mar;25(2):315-325. doi: 10.1007/s40257-023-00816-1. Epub 2023 Oct 7. Am J Clin Dermatol. 2024. PMID: 37804472 Free PMC article.
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L; PredART Trial Team. Meintjes G, et al. Among authors: buyze j. N Engl J Med. 2018 Nov 15;379(20):1915-1925. doi: 10.1056/NEJMoa1800762. N Engl J Med. 2018. PMID: 30428290 Free article. Clinical Trial.
First-line tuberculosis treatment with double-dose rifampicin is well tolerated.
Maug AKJ, Hossain MA, Gumusboga M, Decroo T, Mulders W, Braet S, Buyze J, Arango D, Schurmans C, Herssens N, Demeulenaere T, Lynen L, de Jong BC, Van Deun A. Maug AKJ, et al. Among authors: buyze j. Int J Tuberc Lung Dis. 2020 May 1;24(5):499-505. doi: 10.5588/ijtld.19.0063. Int J Tuberc Lung Dis. 2020. PMID: 32398199 Clinical Trial.
79 results